|
Apr 16
|
Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study
|
|
Apr 16
|
Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why
|
|
Apr 12
|
RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
|
|
Apr 12
|
Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag
|
|
Apr 9
|
Eyenovia (EYEN) Down 18% on Disappointing Corporate Update
|
|
Apr 8
|
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
|
|
Apr 8
|
Wall Street Analysts See a 218.92% Upside in Annovis Bio (ANVS): Can the Stock Really Move This High?
|
|
Apr 2
|
Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
|
|
Apr 1
|
Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
|
|
Mar 21
|
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 211.71%: Read This Before Placing a Bet
|
|
Mar 20
|
Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
|
|
Mar 18
|
Are Options Traders Betting on a Big Move in Annovis Bio (ANVS) Stock?
|
|
Jan 30
|
Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
|
|
Dec 21
|
These Stocks under $10 Are Poised To Explode
|
|
Dec 5
|
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
|
|
Dec 1
|
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
|
|
Dec 1
|
Annovis Bio Appoints Andrew Walsh as Vice President Finance
|
|
Nov 27
|
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
|
|
Nov 8
|
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
|
|
Nov 2
|
Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients
|